Abstract
Throughout the years, people with diabetic macular oedema (DMO) have seen the number of options for their treatment increasing. Laser photocoagulation was the first of these and great experience is behind it; intraocular steroids followed and more recently anti-vascular endothelial growth factor (anti- VEGF) agents came to light. Ophthalmologists face now the dilemma of determining which may be the best therapeutic strategy for each particular patient based on best available evidence. This article summarises data available from randomised clinical trials (RCTs) on treatments for DMO and provides some facts about this condition and its treatments that need to be taken into consideration when treatment decisions are made.
| Original language | English |
|---|---|
| Article number | 2 |
| Journal | Annals of Eye Science |
| Volume | 3 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 05 Jan 2018 |
Bibliographical note
Publisher Copyright:© 2018 AME Publishing Company. All rights reserved.
Keywords
- Anti-vascular endothelial growth factor (anti-VEGF)
- Diabetic macular edema (DME)
- Diabetic macular oedema (DMO)
- Diabetic retinopathy
- Laser photocoagulation
- Randomised clinical trials (RCTs)
- Retina
ASJC Scopus subject areas
- Ophthalmology
Access to Document
- Treatment for diabetic macular oedema: looking further into the evidence
Copyright 2021Annals of Eye Science. This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.